442685-53-2

Usage

Uses

Used in Organic Synthesis:
1H-Indole-1-carboxylic acid, 5-(bromoMethyl)-, 1,1-dimethylethyl ester is used as a building block in organic synthesis for the creation of various biologically active molecules. Its unique structure and functional groups allow for the development of new compounds with potential applications in various industries.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1H-Indole-1-carboxylic acid, 5-(bromoMethyl)-, 1,1-dimethylethyl ester is utilized as a key intermediate in the synthesis of new drugs and pharmaceutical products. Its versatility and stability make it an ideal candidate for drug development, contributing to the discovery of novel therapeutic agents.
Used in Drug Development:
1H-Indole-1-carboxylic acid, 5-(bromoMethyl)-, 1,1-dimethylethyl ester has potential applications in the development of new drugs and pharmaceutical products. Its unique chemical properties and reactivity make it a valuable component in the design and synthesis of innovative therapeutic agents, addressing unmet medical needs and improving patient outcomes.

Upstream product

• 129822-49-7 5-methylindole-1-carboxylic acid tert-butyl ester 
• 279255-90-2 tert-butyl 5-(hydroxymethyl)-1H-indole-1-carboxylate 
• 614-96-0 5-methyl-1H-indole 
• 33140-84-0 methyl 2-(1H-indol-5-yl)acetate 
• 24424-99-5 di-tert-butyl dicarbonate 

Relevant academic research and scientific papers

THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION

Disclosed herein are compounds of formula I: or a salt thereof and compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods for treating or preventing a bacterial infection in an animal comprising administering to the animal a compound of formula I or a pharmaceutically acceptable salt thereof, alone or in combination with a bacterial efflux pump inhibitor.

Antagonists of the human A2A adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines

Antagonism of the human A2A receptor has been implicated as a point of therapeutic intervention in the alleviation of the symptoms associated with Parkinson's disease. This is thought to occur, at least in part, by increasing the sensitivity of the dopaminergic neurons to the residual, depleted levels of striatal dopamine. We herein describe a novel series of functionalized triazolo[4,5-d]pyrimidine derivatives that display functional antagonism of the A2A receptor. Optimization of these compounds has resulted in improvements in potency, selectivity, and the pharmacokinetic properties of key derivatives. These efforts have led to the discovery of 60 (V2006/BIIB014), which demonstrates strong oral activity in commonly used models of Parkinson's disease. Furthermore, this derivative has shown excellent preclinical pharmacokinetics and has successfully completed phase I clinical studies. This compound is presently undergoing further clinical evaluation in collaboration with Biogen Idec.

SUBSTITUTED PYRIDINONES

Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.

Purine derivatives as purinergic receptor antagonists

Use of a compound of formula (I) wherein R1 is selected from alkyl, aryl, alkoxy, aryloxy, 0thioalkyl, thioaryl, CN, halo, NR5R6, NR4COR5, NR4CONR5R6, NR4CO